On October 21st, Johnson&Johnson announced that its drug Zebeko (Nilaparivabiraterone tablets) has been officially approved by the National Medical Products Administration. As the first and only approved dual effect compound preparation in China, Zebaike combined with prednisone or prednisolone is used to treat adult patients with metastatic castration resistant prostate cancer carrying germline and/or systemic BRCA gene mutations.